Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 5Gynecologic 2Gastrointestinal 2Head & Neck 1Dermatologic 1Breast 1

Conditions

Colorectal Neoplasms 476Carcinoma, Hepatocellular 131Rectal Neoplasms 114Colonic Neoplasms 110Neoplasm Metastasis 62Pancreatic Neoplasms 54Liver Neoplasms 44Stomach Neoplasms 37Neoplasms 37Esophageal Neoplasms 21Carcinoma, Non-Small-Cell Lung 21Colorectal Cancer Metastatic 19Ovarian Neoplasms 15Gastrointestinal Neoplasms 14Breast Neoplasms 13Biliary Tract Neoplasms 13Adenocarcinoma 11Lung Neoplasms 10Carcinoma, Renal Cell 10Digestive System Neoplasms 9Cholangiocarcinoma 9Intestinal Neoplasms 8Melanoma 7Gallbladder Neoplasms 7Glioblastoma 6Endometrial Neoplasms 6Uterine Cervical Neoplasms 5Triple Negative Breast Neoplasms 5Sarcoma 5Prostatic Neoplasms 5

Interventions

pembrolizumab 23Gemcitabine 9Nivolumab 7Carboplatin 7Trastuzumab 6Early Intervention, Educational 6avelumab 5atezolizumab 5Docetaxel 5Cisplatin 5cemiplimab 4Standard of Care 4Psychiatric Rehabilitation 4Paclitaxel 4Methods 4Magnetic Resonance Spectroscopy 4Ipilimumab 4Fluorouracil 4Fluorodeoxyglucose F18 4Cyclophosphamide 4Counseling 4Albumin-Bound Paclitaxel 4tisotumab vedotin 3pertuzumab 3fludarabine 3Taxes 3Radiotherapy 3Polymerase Chain Reaction 3Gene Expression Profiling 3Blood Specimen Collection 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × Bevacizumab × Gastrointestinal × Clear all
NCT05007106 2025-08-14

KEYVIBE-005

Merck Sharp & Dohme LLC

Phase 2 Completed
613 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Toray Industries, Inc

Phase 1 Active not recruiting
138 enrolled
DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡